LifeVantage (NASDAQ:LFVN) Shares Cross Above 200-Day Moving Average – Here’s What Happened

LifeVantage Co. (NASDAQ:LFVN)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $14.71 and traded as high as $17.63. LifeVantage shares last traded at $17.58, with a volume of 249,482 shares.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Lake Street Capital started coverage on shares of LifeVantage in a report on Thursday, December 19th. They set a “buy” rating and a $26.00 target price for the company. Craig Hallum started coverage on shares of LifeVantage in a report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price objective for the company.

LifeVantage Stock Up 4.5 %

The company’s fifty day simple moving average is $20.07 and its 200 day simple moving average is $14.71. The firm has a market capitalization of $220.65 million, a PE ratio of 31.39 and a beta of 0.84.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.14 by $0.08. LifeVantage had a net margin of 3.46% and a return on equity of 34.29%.

LifeVantage Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Monday, March 3rd will be paid a dividend of $0.04 per share. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Monday, March 3rd. LifeVantage’s dividend payout ratio is 28.57%.

Insider Buying and Selling at LifeVantage

In other LifeVantage news, Director Raymond B. Greer sold 8,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $20.15, for a total transaction of $161,200.00. Following the completion of the transaction, the director now owns 99,288 shares of the company’s stock, valued at approximately $2,000,653.20. This trade represents a 7.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 20.65% of the company’s stock.

Hedge Funds Weigh In On LifeVantage

A number of institutional investors and hedge funds have recently made changes to their positions in LFVN. Copeland Capital Management LLC bought a new stake in shares of LifeVantage during the fourth quarter valued at approximately $65,000. Hillsdale Investment Management Inc. increased its position in shares of LifeVantage by 7.3% during the fourth quarter. Hillsdale Investment Management Inc. now owns 14,720 shares of the company’s stock valued at $258,000 after acquiring an additional 1,000 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in shares of LifeVantage during the fourth quarter valued at approximately $282,000. OMERS ADMINISTRATION Corp bought a new stake in shares of LifeVantage during the fourth quarter valued at approximately $284,000. Finally, Millennium Management LLC bought a new stake in shares of LifeVantage during the fourth quarter valued at approximately $574,000. Institutional investors own 35.32% of the company’s stock.

LifeVantage Company Profile

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.